Moderate to severe active RA in adults in combination w/ MTX when response to disease-modifying antirheumatic drugs is inadequate. Monotherapy in case of intolerance to MTX or continued treatment w/ MTX is inappropriate. Severe, active & progressive RA in adults not previously treated w/ MTX. Monotherapy or in combination w/ MTX to reduce the rate of joint damage progression as measured by x-ray & improve physical function. Adults w/ severe active ankylosing spondylitis who have had inadequate response to conventional therapy. Adults w/ moderate to severe plaque psoriasis who failed to respond to, or contraindicated or intolerant to other systemic therapy including ciclosporin, MTX or PUVA.
SCRA & ankylosing spondylitis 25 mg twice wkly or 50 mg once wkly. Plaque psoriasis 25 mg twice wkly or 50 mg once wkly. Alternatively, 50 mg twice wkly for up to 12 wk, followed by 25 mg twice wkly or 50 mg once wkly may be used if necessary. Continue up to 24 wk until remission is achieved.
History of recurring or chronic infections or underlying conditions that may predispose patients to infections (eg, advanced or poorly controlled diabetes). Evaluate patients for active & inactive (latent) TB prior to treatment. Risk of reactivation on patients previously infected w/ HBV. Patients w/ history of hepatitis C; blood dyscrasias; malignancy or who develop malignancy. Discontinue use if any serious allergic or anaphylactic reaction occurs; blood dyscrasias are confirmed. Immunosuppression & CHF. Periodic skin exam for all patients particularly those w/ risk factors for skin cancer. May result in the formation of autoimmune antibodies. Patients w/ preexisting or recent onset of demyelinating disease or those w/ increased risk of developing demyelinating disease. Not to be used in treatment of alcoholic hepatitis. Not recommended for the treatment of Wegener's granulomatosis. Hypoglycaemia in patients treated for diabetes. Not recommended in concomitant use w/ anakinra; abatacept. Not to be given concurrently w/ live vaccines. Renal & hepatic impairment. Use appropriate contraception during & 3 wk after therapy in women of childbearing potential. Not recommended during pregnancy. Lactation. May cause inflammatory bowel disease & uveitis in juvenile idiopathic arthritis patients. Elderly.
Sign Out
